Member Info for Barnacle

Worth noting that Panmure Liberum have a target price of 60p.

From the Annual Report:

India

During the period the Company was successful in its application to import Bleepa® as a medical device into India, which was a dependency that needed to be delivered before we could sell Bleepa® in India. This approach required the Company to establish a wholly owned, in-country subsidiary as a vehicle which could then import Bleepa® from the Company and which was necessary to protect our intellectual property, which would have been exposed if we had pursued the faster alternative strategy of exporting the product to a third-party Indian wholesaler. Receiving the import license has enabled our newly appointed in-country Managing Director, Rohit Singh, to start commercialising Bleepa® and begin to address the enormous market opportunity for our technology in India, targeted at sales to hospital groups and to enable national TB screening programmes, with a potential estimated TAM of £8bn.

Rohit Singh, Managing Director of India, has successfully engaged a number of customers both on the use of Bleepa® as a communication tool within hospitals, and as a health corridor between hospitals and for the facilitation of TB screening in remote communities across India. The typical commercial journey in India is to establish a short 3-6-month free pilot with individual customers and then convert to a rolling multi-year contract. In addition to contracts with commercial hospital groups the Company is also pursuing contracts with regional and state governments that typically have to go through competitive procurement, as in the UK, procurement that is typically informed by pilots and therefore the same approach of pilot-contract will be adopted across both public and private sectors.

The contract size potential of individual state contracts however is extremely large, with many states being of an equivalent size to the entire UK population or larger. Based on Rohit’s early success we hope to soon be in a position to announce meaningful pilot contracts across multiple healthcare sectors with a view to converting these to paid contracts as soon as possible. TB screening will be funded through corporate social responsibility (CSR) sponsored programmes initially, before hopefully being adopted by regional and national screening programmes. CSR funding is a robust mechanism in India as we believe that companies above a certain threshold have to spend 1% of their annual profits on CSR activity, creating a large capital resource to drive programs such as TB screening. Rohit, in partnership with the Heal Foundation, is actively pursuing CSR sponsors to drive the screening programmes in several states.

Someone's just matched my earlier buy, nice.

Dibs, there was some confusion over the duration of the QVH contract, from the Annual Results:

"During the period we were invited to provide evidence generated by our pilot with QVH in Sussex to the APPG for Diagnostics, a participation that raised our national profile and opened conversations with the NHSE CDC team, culminating in the award of central funding to support a series of pilot projects with different providers. Our pilot with QVH was extended during the period and has subsequently converted to a £495k annual contract post period end."

What's ticking....!!? ;0)

With regard to India, Feedback recently advertised for 2 new positions based in Haryana, India; an Integration & Customer Support Engineer, and a Full Stack Developer, which would suggest that something is imminent. Coupled with Rory Shaw's visit, it could be that contracts are in the process of being formulated...

From the RNS dated 25 March 2024, and in collaboration with the HEAL foundation, visited a few weeks ago by Rory Shaw, (who also increased his holding in the latest placing...)

New tuberculosis partnership in India

· Partnership focused on delivering CSR and donor funded screening projects

· Aim to develop a digital model that is able to scale at pace

"Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces a new partnership with the HEAL Foundation in India, to deliver community based TB screening projects, funded initially by third-party donors, to support the government's goal of eradicating tuberculosis ("TB") by 2025.

With the Company's unique field-based diagnostic and pathway capabilities and HEAL Foundation's pioneering on-the ground approach, the aim is to bring a 21st century screening service to every community in India, even to the most remote of communities. The focus of this partnership is to develop and drive a digital model, that is able to scale at pace, and build the case for increasing the role of technology to deliver TB screening in India, which has a population of over one billion. This will likely initially be in the form of part-funded pilot studies, which the Company anticipates would cover its core project costs, to validate the digital model ahead of commercial contracts.

Feedback is aiming to provide India with a digital first screening model that harnesses the speed and accuracy of X-ray imaging, supported by AI diagnostics. Effective screening requires asymptomatic cases in all areas of society, and we believe the only way to deliver this is via X-ray imaging performed right in the heart of the community."

I've decided to jump back in. Too much potential to ignore when all eyes in Government are on reducing waiting times and improving patient pathways.

The next few month should be very exciting, and like you Bill, I've got a feeling that we could also be getting news on the India front soon......

Well there you go, an incredible year for Trufin and especially Playstack, a money making machine!

No idea about the commercial details with Apple, except they obviously take a cut of sales...

Here's a very interesting article on how well Balatro has sold during December '24, bodes well for Final Results, should be ahead of forecast in previous trading update.

https://gameworldobserver.com/2024/12/28/balatro-record-peak-ccu-38-5k-steam-crazy-december

On the 4th December Steam downloads were 2.5M units at a gross revenue of $28.6M. As of yesterday Steam Downloads reached 3M units sold at a gross revenue of $34.5M. And this is just on Steam!

As mentioned, both Android and iOS have both had a similar surge of sales during December. Not forgetting the other games in Playstack's catalogue which will also be adding to revenue over this busy period.

I would expect another Trading Update next week.

Https://www.pcgamer.com/games/roguelike/game-of-the-year-2024-balatro/

Great news, will hopefully lead to another surge in sales.

Somethings brewing... Maybe they have won one or both of the tenders below..?

Fingers crossed for the Game Awards tomorrow...!

Looks like a £2M Buy gone through.......

From Linkedin today:

Big news! We’re excited to announce that Playstack will be publishing Darkwater, a cooperative extraction horror game developed by the incredibly talented Targon Studios!

We were fortunate to debut the reveal trailer at yesterday’s PC Gaming Show: Most Wanted, sharing a first look at this exciting project with the gaming world! 🎮

Less we forget, the Manufacturing Facility at Seven Springs holds huge value, something that Dr Cooley obviously found attractive: He has invested £880k in CAP-XX to date and has a 9.98% shareholding. Murata had invested more than US$100m in these supercapacitor manufacturing assets and CAP-XX management, at the time of the transaction, estimated the replacement cost of the third-generation manufacturing lines at A$50m to A$100m

The facility has low production reject rates and management estimates there is spare capacity of 60% at the facility which is currently operating on a single shift basis. At the time of the acquisition, the manufacturing assets had a maximum capacity of more than 6.7m units per annum on a single shift basis. Using an indicative selling price of A$3.40 per unit, this equated to c. A$23m per annum of potential revenue on a single shift basis.

If Balatro wins Game of the Year Award on the 13th Dec, we will be seeing another trading update as sales will go Ballistic!

Panmure Liberum has re-iterated it's BUY rating and increase the target price from 110p to 115p.

Chart looking good, onwards and upwards!

Easy to miss StM, but it will be a real breakthrough in energy density in supercaps....

Should be producing samples mid 2024, so the article says :0)

https://passive-components.eu/cap-xx-signs-joint-venture-with-graphene-specialist-ionic-industries-to-increase-energy-density-in-supercapacitors/

CAP-XX’s supercapacitors utilizing Ionic’s rGO material are expected to serve various applications, including both electric and internal combustion engine vehicles, microgrid storage, smart meters, electronic locks, asset trackers and IoT devices. Additionally, rGO materials are expected to have applications across various hybrid capacitors and batteries. CAP-XX expects to have samples of its supercapacitors featuring the innovative rGO material ready for customers by mid-2024.

Also worth a read, despite being published 2 years ago. This should be coming to fruition soon...

https://ukinvestormagazine.co.uk/cap-xx-a-real-burst-of-energy-is-now-offered-by-this-penny-stock/

Early in May the CAP-XX group announced that it had entered into a Joint Venture Agreement with Ionic Industries for the commercialisation of reduced graphene oxide materials (rGO) for supercapacitors and other energy storage devices.

Ionic, which is another Australian company but based in Melbourne, has under a licence for rGO, developed new forms of graphene for transformational energy storage technologies.

The JV, 51% to CAP-XX and 49% Ionic, will buy rGO products from Ionic, while CAP-XX will manufacture and sell supercapacitors and energy storage devices using rGO on behalf of the JV.

The rGO material is highly conductive, which increases electrode energy density by over 100% compared to CAP-XX’s current electrode. That approaches the energy density of lead acid batteries, providing superior power density and cycle life.

Boss of CAP-XX, Anthony Kongats, stated that

“We are delighted to have formed this joint venture with Ionic, which gives CAP-XX the opportunity to commercialise a new class of supercapacitors with significantly higher energy densities using Ionic’s proprietary reduced graphene oxide. Our immediate goal is to translate the rGO technology into a system that can meet all the stringent performance and specification requirements of commercial supercapacitors.”